Bluechiip Engages MZ Group for Investor Relations
MELBOURNE, Australia, March 18, 2013 /PRNewswire/ — Bluechiip Limited (ASX: BCT) (“Bluechiip,” or the “Company”), a developer and manufacturer of a unique chain of custody tracking and monitoring system initially for the healthcare and life sciences sector, today announced that it has retained MZ Group as its investor relations advisor in Australia and the U.S.
MZ Group will assist Bluechiip with communicating its corporate strategy, financial developments and technology advancements to shareholders and investors, as well as expanding its shareholder base, particularly in North America.
“Our expanding presence in the U.S. and acceleration in customer interest worldwide makes MZ an ideal investor relations partner,” stated Brett Schwarz, Chief Executive Officer of Bluechiip. “After spending the last nine years developing our proprietary, MEMS-based chain of custody tracking and monitoring system, we have started to ramp our commercialization efforts, with an initial focus on the dynamic and growing biobanking and biorepository markets. With established leaders such as STMicroelectronics and Plexus as our manufacturing partners, Early Adopter Program (EAP) partners of ATCC and Gentris and Micronic America as a distributor, we are well positioned to achieve success in this multi-billion dollar market.”
Ted Haberfield, President of MZ Group North America, stated, “Bluechiip possesses all of the qualities we look for in an ideal client – a differentiated technology in a large and growing market; a scalable and highly profitable business model; a seasoned management team; and a solid capital position. We will leverage our strong presence in Australia and North America to help Bluechiip expand their shareholder base and achieve the valuation commensurate with an emerging technology company.”
About Bluechiip Limited
Bluechiip has developed a wireless tracking solution for the healthcare and life science, security, defence and manufacturing industries which represents a generational change from current methods such as labels (hand-written and pre-printed), barcodes (linear and 2D) and microelectronic integrated circuit (IC)-based RFID (Radio Frequency Identification).
The unique tag is based on MEMS technology and contains no electronics. The tag can either be embedded or manufactured into a storage product, such as vials or bags. Easy identification, along with any associated information from the tag such as temperature can be detected by a reader, which can also sense the temperature of the tagged items. The traditional identification technologies have significant limitations. Whereas a barcode requires a visible tag or line-of-sight optical scan, bluechiip(®) technology does not. Unlike labels, barcodes and RFID, the bluechiip(®) technology can sense the temperature of each item a tag is attached to, or embedded in.
The bluechiip(®) technology has initial applications in the healthcare industry particularly those businesses which require cryogenic storage facilities (biobanks and biorepositories). bluechiip(®) offers the only technology that enables accurate and reliable tracking of products including stem cells, cord blood, and other biospecimens. In addition to functioning in extreme temperatures, the bluechiip(®) tracking solution can survive autoclaving, gamma irradiation sterilization, humidification, centrifuging, cryogenic storage and frosting.
The bluechiip(®) technology has other healthcare applications in pathology, clinical trials and forensics. Several other key markets outside of healthcare include cold-chain logistics/supply chain, security/defence, industrial/manufacturing and aerospace/aviation.
Further information is available at www.bluechiip.com.
About MZ Group
MZ Group, subsidiary of @titude Global, a multinational company and the world’s largest independent global investor relations consulting firm, provides investor relations, corporate communications, market intelligence, corporate governance and technology products and services. Founded in 1999, MZ Group focuses on innovation and personalized services, supported by its exclusive “one-stop-shop” business model. With offices in SÃ£o Paulo, New York, Chicago, San Diego, Vancouver, Hong Kong, Beijing, Shanghai, Taipei and Mumbai, MZ has approximately 350 professionals who serve over 580 clients in 12 countries. For more information, please visit www.mzgroup.com.
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this release that are not historical facts, including, without limitation, statements that relate to the Company’s expectations with regard to the future impact on the Company’s results from new products in development, may be deemed to be forward-looking statements. Words such as “expects”, “intends”, “plans”, “may”, “could”, “should”, “anticipates”, “likely”, “believes” and words of similar import also identify forward-looking statements. These statements are subject to risks and uncertainties. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined and assumptions of management. Readers are urged not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. Except as may be required under applicable law, we assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release. Additional information on risks and other factors that may affect the business and financial results of Bluechiip Limited can be found in the filings of Bluechiip Limited with the Australian Securities Administrators and the Australian Stock Exchange at www.asx.com.au.
Error occurred while generating ASCII Content for table
SOURCE Bluechiip Limited